7 results about "Complement activity" patented technology

This invention provides a pharmaceutical composition for use in a method of preventing antibody-mediated rejection (ABMR) in subjects who have undergone solid organ transplantation by preventing complement activity. [Solution] A pharmaceutical composition comprising an anti-human interleukin-6 (IL-6) antibody or an anti-human IL-6 antibody fragment for use in a method of preventing, stabilizing, or reducing complement activity in a subject who is scheduled to receive, has received, or has received a solid organ transplant, wherein the method comprises administering to a subject a prophylactic or therapeutically effective amount of the antibody or antibody fragment, the pharmaceutical composition comprising a variable light chain polypeptide containing a CDR of a specific sequence, and a variable heavy chain polypeptide containing a CDR of a specific sequence.

Novel anti-C3 antibodies and anti-C5 antibodies are provided that are capable of modulating complement activity by specifically binding to the human complement factors C3, C3a, C3b and / or C5. Also described herein are recombinant adeno-associated virus (AAV) (rAAV) comprising a variant adeno-associated virus (AAV) capsid and a transgene encoding an anti-C3 antibody and / or an anti-C5 antibody. Also provided are methods of delivering a transgene to the retina, as well as methods of treating dry age-related macular degeneration and map-like atrophy secondary to an age-related macular degeneration disorder by contacting retinal cells with rAAV.

The present disclosure relates to proteins comprising antigen binding sites that bind to human complement C2 (C2). The present disclosure also relates to methods of inhibiting complement activity in a subject as well as methods of treating or preventing complement-mediated disorders.

The use of urine C5b-9 (uC5b-9) as a highly accurate and superior biomarker that is well correlated to complement activity in local tissue affected by complement-mediated diseases (e.g., diseases with renal lesion components) is provided. The biomarkers may be used, for example, in the absence of systemic complement inhibition, to treat and / or monitor diseases mediated by such complements using complement inhibitors targeted to local tissue affected by such complements.

The invention relates to a complement activity regulator as well as a preparation method and medical application thereof, in particular to a binding polypeptide as shown in a general formula (I) and a derivative thereof, or a medicinal salt and a pharmaceutical composition thereof, and application of the binding polypeptide and the derivative thereof in preparation of medicines for preventing or treating complement-related diseases or symptoms.

The invention belongs to the field of traditional Chinese medicine preparation, and relates to application of dicoumarin compounds daphnoretin and 3-hydroxy-6-methoxy-7, 7 '-dicoumarin ether in preparation of anticomplement drugs. According to the invention, biscoumarin compounds, namely daphnoretin and 3-hydroxy-6-methoxy-7, 7 '-biscoumarin ether, are extracted from an n-butyl alcohol extraction part of an ethanol extract of dried roots of Stellera tianshanica (Stellera tianshanica. Pored.), and the biscoumarin compounds, namely the daphnoretin and the 3-hydroxy-6-methoxy-7, 7'-biscoumarin ether are extracted from the n-butyl alcohol extraction part of the ethanol extract of the dried roots of Stellera tianshanica. An in-vitro anti-complement activity evaluation experiment proves that the compound has a relatively strong inhibition effect on both a classical pathway and a bypass pathway of a complement system. The biscoumarin compound daphnoretin and the 3-hydroxy-6-methoxy-7, 7 '-biscoumarin ether disclosed by the invention can be further used for preparing medicines for treating complement related diseases, and the complement related diseases comprise systemic lupus erythematosus, rheumatoid arthritis or acute respiratory distress syndrome.

Novel anti-C3 and anti-C5 antibodies are provided that can modulate complement activity by specifically binding to human complement factors C3, C3a, C3b, and / or C5. Recombinant AAVs (rAAVs) containing variant adeno-associated virus (AAV) capsids and transgenes encoding anti-C3 and / or anti-C5 antibodies are also described herein. Methods for delivering transgenes to the retina by contacting retinal cells with rAAVs, as well as methods for treating atrophic age-related macular degeneration and geographic atrophy secondary to age-related macular degeneration disorders, are also provided.